Delayed aneurysm rupture (DAR) is a potentially devastating complication after flow-diverters (FD) deployment and their exact mechanisms are still unclear. The purpose of this meta-analysis is to synthesize the latest evidence on DAR after FD treatment and identify predictive factors.

The optimal thrombectomy technique for medium/distal vessel occlusions (MDVOs) remains uncertain.

Advancement in neurointervention is frequently driven by the introduction of new technology and devices that improve procedural efficacy and patient outcomes. For physician-innovators, customer discovery-or the process of directly engaging with end users to explore workflows and associated challenges-offers a structured way to identify meaningful problems and guide early innovation. This primer aims to outline stepwise guidance for conducting customer discovery within neurointervention to characterize key areas of unmet need.

Venous manometry (VM) is the reference standard for confirming hemodynamically significant transverse sinus stenosis (TSS) in idiopathic intracranial hypertension (IIH). However, no standardized approach exists for triaging refractory IIH (rIIH) patients for VM, and current IIH diagnostic criteria were not designed for this purpose. We evaluated the performance of established IIH diagnostic frameworks and imaging markers in detecting VM-confirmed TSS (vTSS).

Wide-necked intracranial aneurysms present unique challenges for endovascular treatment. The Comaneci device is a novel temporary bridging device designed to assist coil embolization without parent vessel occlusion.

Endovascular treatment (EVT) is an important treatment for symptomatic intracranial atherosclerotic stenosis (sICAS). However, restenosis limits its long-term efficacy, and some patients continue to experience ischemic events, requiring more aggressive interventions.

Flow diversion is an effective technique for treating intracranial aneurysms (IAs), with a high rate of complete aneurysm occlusion at 1 year. As dual antiplatelet treatment (DAPT) is required, it is restricted to unruptured IA. Surface-modification (SM) flow diverters (FDs), introduced to reduce thrombogenicity, have been poorly evaluated. COATING (Coating to Optimize Aneurysm Treatment In the New Flow Diverter Generation) is the first randomized controlled trial (RCT) evaluating an SM FD (p64-MW-HPC (hydrophilic polymer coating), phenox GmbH) under single antiplatelet treatment (SAPT).

Pretreatment with dual antiplatelet agents (DAPT) has been standard practice for patients undergoing aneurysm treatment with flow diversion (FD). Rates of periprocedural diffusion lesions observed after FD procedures remain high (>50%). We assessed the feasibility of intraprocedural eptifibatide as an alternative to standard preprocedural DAPT.

Dynamic internal jugular vein (IJV) stenosis has been demonstrated with 90 degree head rotation, often producing large trans-stenotic pressure gradients and elevations in intracranial venous pressures. However, the prevalence of IJV stenosis and occlusion with partial head rotation remains unknown.

Whether perfusion 'mismatch' modifies the effect of endovascular thrombectomy (EVT) in patients with large core ischemic stroke remains uncertain.

The Magic microcatheter is a commonly used flow directed microcatheter for endovascular neurointervention. This microcatheter family is one of the smallest and softest microcatheters on the market, suitable for embolization of fistulous lesions in pediatric patients. Despite the Magic catheter being designed for adult size and lengths, our institution regularly utilizes these catheters for pediatric and neonatal embolizations. In some geographical regions, the Magic microcatheter remains contraindicated for use in pediatrics and neonates.

Mechanical thrombectomy (MT) is a well-established treatment for acute ischemic stroke (AIS) due to large vessel occlusion (LVO). However, its role in cervical artery dissection-related (CeAD) LVO remains debated due to anatomical complexities and procedural challenges. This systematic review and meta-analysis aims to evaluate the safety, efficacy, and clinical outcomes of MT in patients with AIS due to CeAD-related LVO compared with other AIS etiologies.